1-20 of 101
Jun Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO1-01-02: Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course trastuzumab/pertuzumab for HER2-positive breast cancer: a single-arm, phase II study

Yaping Yang, Liang Jin, Yudong li, Fengxia Gan, Nanyan Rao, Jun Zhang, Ruifa Feng, Zhenzhen Liu, Qiang Liu
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-01-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-01-02
Published: 02 May 2024
View article titled, Abstract PO1-01-02: Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course trastuzumab/pertuzumab for HER2-positive breast cancer: a single-arm, phase II study
Journal Articles

Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

Byoung Chul Cho, Shun Lu, Myung Ah Lee, Zhengbo Song, John Park, Sun Min Lim, Ziming Li, Jun Zhao, Gary Richardson, Yanqiao Zhang, Jun Zhang, Anwen Liu, Cheng Chen, Jia Wang, Jingtao Lu, Haopeng Rui, Qian Chen, Hui Wang, Jing Zhang, Zhi Jian Chen, Tony Mok
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT117.
https://doi.org/10.1158/1538-7445.AM2024-CT117
Published: 05 April 2024
View article titled, Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
Journal Articles

Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C

Junwei Wu, Chenfei Zhou, Jun Yan, Zhengxiang Han, Chun Wang, Zhiquan Qin, Jinling Jiang, Chunbin Wang, Xinyu Tang, Lingjun Zhu, Jun Chen, Yong Mao, Xiaowei Wei, Chengfang Shangguan, Jun Zhang
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT213.
https://doi.org/10.1158/1538-7445.AM2024-CT213
Published: 05 April 2024
View article titled, Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Journal Articles

Abstract 4375: ALPPL2 is involved in MAPK signal pathway of pancreatic cancer

Ke Wei Gong, Bilal Hamid, Kenny W. Castro, Martina S. McDermott, Forrest Epstein, Kevin Chau, Chuhong Hu, Jun Zhang, Ming Lu, Benjamin G. Hoffstrom, Neil A. O'Brien, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4375.
https://doi.org/10.1158/1538-7445.AM2024-4375
Published: 22 March 2024
View article titled, Abstract 4375: ALPPL2 is involved in MAPK signal pathway of pancreatic cancer
Journal Articles

Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)

Martina S. McDermott, Neil A. O'Brien, Ming Lu, Jun Zhang, KeWei Gong, Benjamin Hoffstrom, Tong Luo, Min Liang, Weiping Jia, Kevin Chau, Leonard Presta, John Glaspy, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1896.
https://doi.org/10.1158/1538-7445.AM2024-1896
Published: 22 March 2024
View article titled, Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)
Journal Articles

Abstract 4912: Unsupervised detection of stromal phenotypes with distinct fibrogenic and inflamed properties in NSCLC

Neel Patel, Nhat Le, Tan Nguyen, Fedaa Najdawi, Sandhya Srinivasan, Adam Stanford-Moore, Deeksha Kartik, Jun Zhang, Jacqueline Brosnan-Cashman, Robert Egger, Justin Lee, Matthew Bronnimann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4912.
https://doi.org/10.1158/1538-7445.AM2024-4912
Published: 22 March 2024
View article titled, Abstract 4912: Unsupervised detection of stromal phenotypes with distinct fibrogenic and inflamed properties in NSCLC
Journal Articles

Abstract 3331: Preclinical combination of ONC206 with radiotherapy and temozolomide in a GBM mouse orthotopic model

Lanlan Zhou, Leiqing Zhang, Jun Zhang, Shengliang Zhang, Wafik S. El-Deiry
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3331.
https://doi.org/10.1158/1538-7445.AM2024-3331
Published: 22 March 2024
View article titled, Abstract 3331: Preclinical combination of ONC206 with radiotherapy and temozolomide in a GBM mouse orthotopic model
Journal Articles

Abstract 1900: TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer

Neil A. O'Brien, Martina SJ McDermott, Jun Zhang, Ming Lu, Ke Wei Gong, Benjamin Hoffstrom, Wei Ping Jia, Tong Luo, Athena M. Madrid, Min Liang, John A. Glaspy, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1900.
https://doi.org/10.1158/1538-7445.AM2024-1900
Published: 22 March 2024
View article titled, Abstract 1900: TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer
Journal Articles

Abstract 4864: Epidemiological characteristics and treatment strategies of gastric cancer with neuroendocrine differentiation (NED)

Zhen Huang, Jinlai Wei, Yifan Shen, Jun Zhang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4864.
https://doi.org/10.1158/1538-7445.AM2024-4864
Published: 22 March 2024
View article titled, Abstract 4864: Epidemiological characteristics and treatment strategies of gastric cancer with neuroendocrine differentiation (NED)
Journal Articles

Development of a Rare Earth Nanoprobe Enables In Vivo Real-Time Detection of Sentinel Lymph Node Metastasis of Breast Cancer Using NIR-IIb Imaging

Yuan-Yuan Zhu, Liang Song, Yong-Qu Zhang, Wan-Ling Liu, Wei-Ling Chen, Wen-Liang Gao, Li-Xin Zhang, Jia-Zheng Wang, Zi-He Ming, Yun Zhang, Guo-Jun Zhang
Journal: Cancer Research
Cancer Res (2023) 83 (20): 3428–3441.
https://doi.org/10.1158/0008-5472.CAN-22-3432
Published: 13 October 2023
View article titled, Development of a Rare Earth Nanoprobe Enables <em>In Vivo</em> Real-Time Detection of Sentinel Lymph Node Metastasis of Breast Cancer Using NIR-IIb Imaging
Open the PDF for Development of a Rare Earth Nanoprobe Enables <em>In Vivo</em> Real-Time Detection of Sentinel Lymph Node Metastasis of Breast Cancer Using NIR-IIb Imaging in another window
Includes: Supplementary data
Journal Articles

Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer

Zhi Peng, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang, Yuxian Bai, Ying Yuan, Tao Wu, Feng Ye, Qinghua Pan, Jufeng Wang, Enxiao Li, Diansheng Zhong, Yueyin Pan, Yanru Qin, Yan Yang, Yusheng Wang, Aiping Zhou, Yongshun Chen, Dianbao Zhang, Hongli Liu, Xiujuan Qu, Shubin Wang, Ning Liu, Jinsheng Wu, Wei Li, Kejun Nan, Hongming Pan, Jianming Xu, Chunmei Bai, Heling Liu, Jia Wei, Runzhi Chen, Rongrong Li, Wei Li, Jinghong Zhou, Hongyan Yin, Qian Xu, Songhua Fan, Yongxin Ren, Weiguo Su, Lin Shen
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT152.
https://doi.org/10.1158/1538-7445.AM2023-CT152
Published: 14 April 2023
View article titled, Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer
Journal Articles

Abstract 5494: Preclinical combination of ONC201 with radiotherapy and Temozolomide in a GBM mouse orthotopic model results in reduced tumor burden and prolonged survival

Lanlan Zhou, Laura Jinxuan Wu, Jun Zhang, Andrew George, Marina Hahn, Leiqing Zhang, Attila A. Seyhan, Wafik S. El-Deiry
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5494.
https://doi.org/10.1158/1538-7445.AM2023-5494
Published: 04 April 2023
View article titled, Abstract 5494: Preclinical combination of ONC201 with radiotherapy and Temozolomide in a GBM mouse orthotopic model results in reduced tumor burden and prolonged survival
Journal Articles

Abstract 6616: Development of a high-throughput image processing pipeline for multiplex immunofluorescence whole slide images at scale

Waleed Tahir, Emma Krause, Jin Li, Howard Mak, Mohammad Mirzadeh, Kevin Rose, Judy Shen, Vignesh Valaboju, Guillaume Chhor, Joseph Lee, Jun Zhang, Jacqueline Brosnan-Cashman, Michael G. Drage, Justin Lee, Carlee Hemphill, Saumya Pant, Robert Egger
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6616.
https://doi.org/10.1158/1538-7445.AM2023-6616
Published: 04 April 2023
View article titled, Abstract 6616: Development of a high-throughput image processing pipeline for multiplex immunofluorescence whole slide images at scale
Journal Articles

Abstract 5510: TAS102 synergizes with regorafenib against colorectal and gastric cancer cells

Jun Zhang, Lanlan Zhou, Shuai Zhao, Wafik S. El-Deiry
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5510.
https://doi.org/10.1158/1538-7445.AM2023-5510
Published: 04 April 2023
View article titled, Abstract 5510: TAS102 synergizes with regorafenib against colorectal and gastric cancer cells
Journal Articles

Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors

Takahiko Akiyama, Tadahito Yasuda, Tomoyuki Uchihara, Noriko Yasuda-Yoshihara, Benjy J.Y. Tan, Atsuko Yonemura, Takashi Semba, Juntaro Yamasaki, Yoshihiro Komohara, Koji Ohnishi, Feng Wei, Lingfeng Fu, Jun Zhang, Fumimasa Kitamura, Kohei Yamashita, Kojiro Eto, Shiro Iwagami, Hirotake Tsukamoto, Terumasa Umemoto, Mari Masuda, Osamu Nagano, Yorifumi Satou, Hideyuki Saya, Patrick Tan, Hideo Baba, Takatsugu Ishimoto
Journal: Cancer Research
Cancer Res (2023) 83 (5): 753–770.
https://doi.org/10.1158/0008-5472.CAN-22-1890
Published: 02 March 2023
View article titled, Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors
Open the PDF for Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract P5-02-09: Quantitative analysis of fiber-level collagen features in H&E whole-slide images predicts neoadjuvant therapy response in patients with HER2+ breast cancer

Tan H. Nguyen, Mohammad Mirzadeh, Aaditya Prakash, Emma L. Krause, Jun Zhang, Michael Pyle, Esther R. Ogayo, Harry C. Cramer, Busem Binboga Kurt, Jacqueline Brosnan-Cashman, Michael G. Drage, Stuart Schnitt, Andrew H. Beck, Michael Montalto, Ilan Wapinski, Laura Chambre, Sara Tolaney, Adrienne Waks, Justin Lee, Elizabeth A. Mittendorf
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-09.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-09
Published: 01 March 2023
View article titled, Abstract P5-02-09: Quantitative analysis of fiber-level collagen features in H&amp;E whole-slide images predicts neoadjuvant therapy response in patients with HER2+ breast cancer
Journal Articles

PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma

Jun-Cheng Wang, Dong-Ping Chen, Shi-Xun Lu, Jin-Bin Chen, Yuan Wei, Xue-Chao Liu, Yu-Hao Tang, Rongxin Zhang, Jian-Cong Chen, Anna Kan, Li Xu, Yao-Jun Zhang, Jiajie Hou, Dong-Ming Kuang, Min-Shan Chen, Zhong-Guo Zhou
Journal: Cancer Research
Cancer Res (2022) 82 (18): 3307–3320.
https://doi.org/10.1158/0008-5472.CAN-21-3899
Published: 16 September 2022
View article titled, PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma
Open the PDF for PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers

Martina S. McDermott, Ke Wei Gong, Neil A. O'Brien, Dylan Conklin, Benjamin Hoffstrom, Ming Lu, Jun Zhang, Tong Luo, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Michael F. Press, Abram Handly-Santana, Joan S. Brugge, Ronny Drapkin, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 342.
https://doi.org/10.1158/1538-7445.AM2022-342
Published: 15 June 2022
View article titled, Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers
Journal Articles

Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers

Neil A. O'brien, Martina S. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin G. Hoffstrom, Dylan Conklin, Tong Luo, Kevin Chau, Min Liang, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 332.
https://doi.org/10.1158/1538-7445.AM2022-332
Published: 15 June 2022
View article titled, Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers
Journal Articles

Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

Neil A. O'Brien, Holly K. Huang, Martina S. McDermott, Athena Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB197.
https://doi.org/10.1158/1538-7445.AM2022-LB197
Published: 15 June 2022
View article titled, Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies